Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) EBIT (2021 - 2025)

Lucid Diagnostics (LUCD) has disclosed EBIT for 5 consecutive years, with -$11.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT fell 0.56% year-over-year to -$11.8 million, compared with a TTM value of -$48.0 million through Sep 2025, down 6.37%, and an annual FY2024 reading of -$46.1 million, up 5.01% over the prior year.
  • EBIT was -$11.8 million for Q3 2025 at Lucid Diagnostics, down from -$11.4 million in the prior quarter.
  • Across five years, EBIT topped out at -$3.7 million in Q1 2021 and bottomed at -$15.0 million in Q4 2022.
  • Average EBIT over 5 years is -$11.3 million, with a median of -$11.6 million recorded in 2023.
  • The sharpest move saw EBIT tumbled 235.92% in 2022, then rose 24.62% in 2024.
  • Year by year, EBIT stood at -$11.2 million in 2021, then crashed by 33.52% to -$15.0 million in 2022, then grew by 23.69% to -$11.5 million in 2023, then dropped by 8.05% to -$12.4 million in 2024, then increased by 4.98% to -$11.8 million in 2025.
  • Business Quant data shows EBIT for LUCD at -$11.8 million in Q3 2025, -$11.4 million in Q2 2025, and -$12.5 million in Q1 2025.